Patent Issued for Methods of treating cancer using PRMT5 inhibitors (USPTO 11571437).

This correlation turns PRMT5 into an important small molecule drug target against cancer and other diseases. There is thus a strong need for novel treatment regimens involving PRMT5 inhibitors for the treatment or prevention of cancer. Keywords: Alicyclic Hydrocarbons; Amino Acids; Arginine; Basic Amino Acids; Business; Cancer; Cycloparaffins; Cyclopentanes; Diamino Amino Acids; Drugs and Therapies; Enzymes and Coenzymes; Essential Amino Acids; Genetics; Health and Medicine; Hydrocarbons; Janssen Pharmaceutica NV; Methyltransferases; Oncology; One-Carbon Group Transferases; Organic Chemicals; Pharmaceutical Companies; Risk and Prevention; Therapeutics; Therapy EN Alicyclic Hydrocarbons Amino Acids Arginine Basic Amino Acids Business Cancer Cycloparaffins Cyclopentanes Diamino Amino Acids Drugs and Therapies Enzymes and Coenzymes Essential Amino Acids Genetics Health and Medicine Hydrocarbons Janssen Pharmaceutica NV Methyltransferases Oncology One-Carbon Group Transferases Organic Chemicals Pharmaceutical Companies Risk and Prevention Therapeutics Therapy 1822 1822 1 03/24/23 20230228 NES 230228 2023 FEB 28 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Janssen Pharmaceutica NV (Beerse, Belgium) has been issued patent number 11571437, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. [Extracted from the article]